Overexpression of the HMGA2 gene in transgenic mice leads ... - Nature

ã

Oncogene (2002) 21, 3190 ± 3198 2002 Nature Publishing Group All rights reserved 0950 ± 9232/02 $25.00 www.nature.com/onc

Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas Monica Fedele1,2, Sabrina Battista1,2, Lawrence Kenyon3, Gustavo Baldassarre2, Vincenzo Fidanza2, Andres JP Klein-Szanto4, AF Parlow5, Rosa Visone1, Giovanna M Pierantoni1, Eric Outwater6, Massimo Santoro1, Carlo M Croce2 and Alfredo Fusco*,1,7 1

Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o Centro di Endocrinologia ed Oncologia Sperimentale del CNR, FacoltaÁ di Medicina e Chirurgia di Napoli, UniversitaÁ degli Studi di Napoli «Federico II», Naples, Italy; 2Kimmel Cancer Center, Jeerson Medical College, Philadelphia, Pennsylvania, USA; 3Department of Pathology, Thomas Jeerson University Hospital, Philadelphia, Pennsylvania, USA; 4Experimental Histopathology, Fox-Chase Cancer Center, Philadelphia, Pennsylvania, USA; 5 National Hormone and Pituitary Program (NHPP), Harbour-UCLA Med Ctr. Torrance, California, USA; 6Image Center, Jeerson Medical College, Philadelphia, Pennsylvania, USA; 7Dipartimento di Medicina Sperimentale e Clinica, FacoltaÁ di Medicina e Chirurgia di Catanzaro, UniversitaÁ di Catanzaro, Catanzaro, Italy

Overexpression of the HMGA2 gene is a common feature of neoplastic cells both in experimental and human models. Intragenic and extragenic HMGA2 rearrangements responsible for HMGA2 gene overexpression have been frequently detected in human benign tumours of mesenchymal origin. To better understand the role of HMGA2 overexpression in human tumorigenesis, we have generated transgenic mice carrying the HMGA2 gene under the transcriptional control of the cytomegalovirus promoter. High expression of the transgene was demonstrated in all the mouse tissues analysed, whereas no expression of the endogenous HMGA2 gene was detected in the same tissues from wild-type mice. In this study, two indipendent lines of transgenic mice have been generated. By 6 months of age, 85% of female animals of both transgenic lines developed pituitary adenomas secreting prolactin and growth hormone. The transgenic males developed the same phenotype with a lower penetrance (40%) and a longer latency period (about 18 months). Therefore, these data demonstrate that the overexpression of HMGA2 leads to the onset of mixed growth hormone/ prolactin cell pituitary adenomas. These transgenic mice may represent an important tool for the study of this kind of neoplasia. Oncogene (2002) 21, 3190 ± 3198. DOI: 10.1038/sj/ onc/1205428 Keywords: transgenic mice; HMGA2; pituitary adenomas; Pit-1; tumorigenesis

*Correspondence: A Fusco, Dipartimento di Biologia e Patologia Cellulare e Molecolare, FacoltaÁ di Medicina e Chirurgia di Napoli, via Pansini 5, 80131 Napoli, Italy; E-mail: [email protected] Received 31 October 2001; revised 4 February 2002; accepted 20 February 2002

Introduction The HMGA2 protein belongs to the High Mobility Group A (HMGA) family. Other members of this family include HMGA1a, HMGA1b and HMGA1c, three dierent isoforms of the HMGA1 gene (Johnson et al., 1989; Nagpal et al., 1999). They are small, non-histone, chromatin-associated proteins that bind DNA in ATrich regions through three basic domains named `AThook'. The HMGA protein family members have no intrinsic transcriptional activity, but they can regulate transcription by altering the architecture of chromatin and facilitating the assembly of multiprotein complexes of transcriptional factors (Thanos and Maniatis, 1995). HMGA gene expression is negligible in normal adult tissues, apart from a very low expression in CD34 positive stem cells (Rommel et al., 1997), and in mouse pre-adipocytic cells (Anand and Chada, 2000), and is essentially restricted to embryonic development (Chiappetta et al., 1996; Zhou et al., 1995). HMGA overexpression has been shown in several human and experimentally induced malignant tumours (Abe et al., 1999, 2000; Bandiera et al., 1998; Chiappetta et al., 1995, 1998, 2001; Fedele et al., 1996; Giancotti et al., 1987). HMGA proteins have a key role in malignant transformation since suppression of HMGA expression, by an antisense methodology, prevents malignant transformation of thyroid cells by acute retroviruses (Berlingieri et al., 1995). Rearrangements of the HMGA2 gene have been frequently detected in human benign tumours of mesenchymal origin, including lipomas, pulmonary hamartomas, uterine leiomyomas, endometrial polyps and ®broadenomas of the breast (Ashar et al., 1995; Bol et al., 1996; Kazmierczak et al., 1995; Schoenmakers et al., 1995; Staats et al., 1996). 12q13 ± 15 chromosomal translocations involving the HMGA2 gene locus, account for these rearrangements. The HMGA2 protein has three AT-hook domains and an

HMGA2 transgenic mice develop pituitary adenomas M Fedele et al

acidic carboxy-terminal tail. The HMGA2 modi®cations consist in the loss of the acidic carboxy-terminal tail and fusion with ectopic sequences. Recent results show that the loss of the carboxy-terminal region, rather than the acquisition of new sequences, is sucient to confer to HMGA2 the ability to transform NIH3T3 cells (Fedele et al., 1998). Moreover, transgenic mice carrying a truncated HMGA2 gene showed a giant phenotype together with abdominal/pelvic lipomatosis (Arlotta et al., 2000; Battista et al., 1999; Fedele et al., 2001). In several human benign tumours, overexpression of the wild type HMGA2 gene following chromosomal translocation has also been detected (Rogalla et al., 1996; Schoenberg Fejzo et al., 1996). However, the role of HMGA2 overexpression in tumorigenesis still needs to be de®ned. Since transgenic mice provide a powerful experimental approach to de®ne the role of oncogenes in neoplastic processes in vivo (Hogan, 1983), we generated transgenic mice carrying the HMGA2 wild type gene under transcriptional control of the cytomegalovirus (CMV) promoter to establish the role of HMGA2 overexpression in tumorigenesis. HMGA2 transgenic mice showed abundant HMGA2 expression in all normal tissues analysed, whereas no expression was observed in control mice. By 6 months of age the large majority (85%) of female HMGA2 mice developed pituitary adenomas secreting prolactin (PRL) and growth hormone (GH). The same phenotype appeared with lower penetrance (40%) and longer latency period (about 18 months) in HMGA2 males. Thus, in independently derived transgenic lines, we demonstrate a key role of HMGA2 overexpression in pituitary tumorigenesis. These mice have the potential to serve as a valuable experimental model for human pituitary adenomas.

Results Generation of transgenic mice overexpressing the HMGA2 gene A wild type HMGA2 cDNA under the transcriptional control of the CMV promoter (Figure 1a) was microinjected into B6C3F2 fertilized eggs and subsequently transferred to pseudopregnant females. Analysis of the ospring, by Southern blot analysis of tail DNAs digested with BamHI and hybridized with a cDNA corresponding to the CMV promoter, led us to identify two potential founders (Figure 1b). They were bred with wild type C57BL/6J mice and two stable lines were obtained. Southern blot analysis con®rmed the integration of the transgene (Figure 1b). Similar numbers of integrated copies were found in both transgenic lines (data not shown). All founders transmitted the transgene in a Mendelian fashion (data not shown). Those ospring that did not inherit the transgene were used in our studies as controls. Transgene expression was analysed by RT ± PCR using total RNA extracted from brown adipose tissue (BAT), heart, pituitary gland, liver, spleen, and kidney (Figure

1c). The transgene expression was observed in all the analysed tissues. The highest expression was observed in spleen, kidney and pituitary gland, whereas the lowest expression was detected in liver tissue. No expression of endogenous HMGA2 was detected in tissues from transgenic (data not shown) or wild type control mice (Figure 1c, lanes 7 and 8), in accordance with previous published results (Battista et al., 1999).

3191

HMGA2 mice develop pituitary adenomas At 12 months of age, most of the HMGA2 transgenic mice showed a deformed skull and several symptoms of head tilt (loss of equilibrium, excessive tear production and general behavioural changes suggestive of headache). Magnetic Resonance Imaging (MRI) analysis showed a large tumour mass in the skull base pushing the brain upward against the cranium and causing an alteration of the normal pro®le (Figure 2a). The mice with evident symptoms of head tilt were sacri®ced and the tumour mass was analysed. In Figure 2b, dorsal and ventral views of a transgenic mouse brain with tumour is shown. A large haemorrhagic mass, spanning 2/3 of the extent of the brain, is located immediately caudal of the optic chiasm. The tumours were friable and easily detached from the surrounding brain tissue and there was no evidence of gross in®ltration of the brain or sphenoid bone. Sections from the tumour samples were paran embedded and stained with hematoxylin and eosin (Figure 2c). The tumours demonstrate a follicular type architecture with numerous blood lakes. The follicles were lined by cuboidal to polygonal cells with eosinophilic cytoplasm and hyperchromatic nuclei. There was no in®ltration of surrounding brain tissue. Usually, at the edges of the tumour there were numerous hemosiderin laden macrophages indicative of remote haemorrhage. A portion of the intermediate lobe of the pituitary could be identi®ed along with its adjacent neurohypophyseal tissue. The intermediate lobe was separated from the tumour cells by a ¯uid ®lled cleft. The tumour cells more closely resemble those of the anterior lobe (adenohypophysis). There was no evidence of any residual adenohypophysis in any of the mice with large tumours. It seems likely that the adenoma totally overgrew the normal gland or that the tumour cells were in®ltrative and markedly expanded the gland. In support of the latter was the ®nding that very small, early tumours demonstrated in®ltration of neoplastic cells into the normal adenohypophysis (data not shown). Accordingly, primary cultures of the tumours showed the typical epithelial phenotype of the adenohypophyseal cells (Bauer et al., 1990) (Figure 2d). Moreover, they were not able to grow inde®nitely in culture or to induce tumorigenesis if injected into nude mice (data not shown). Ultrastructural analysis (Figure 2e) demonstrates a mixed population of polygonal tumour cells displaying varying numbers of neurosecretory type dense core granules compatible with neuroendocrine dierentiation. These morphological ®ndings are typical of a Oncogene


3192

Figure 1 (a) Schematic representation of the CMV/HMGA2 transgene. (b) Analysis of the integration of the CMV/HMGA2 construct by Southern Blot. DNA samples were as follows: lane 1: transgenic founder mouse (F0) #1; lane 2: transgenic F1 mouse from founder #1; lane 3: wild type F1 mouse from founder #1; lane 4: transgenic founder mouse (F0) #2; lane 5: wild type F1 mouse from founder #2; lane 6: transgenic F1 mouse from founder #2. (c) Analysis of the expression of the HMGA2 gene by RT ± PCR. Lanes 1 ± 6: RNAs extracted from dierent tissues of a HMGA2 transgenic mouse; lanes 7 and 8: RNA extracted from a pool of pituitary glands and a spleen of control mice

secreting pituitary adenoma. As shown in Table 1, pituitary adenomas were diagnosed in about 85% of the female transgenic HMGA2 mice by the age of 6 months. Conversely, in transgenic males the pathology appeared with a longer latency period (18 months of age) and a lower penetrance (about 40%). HMGA2-induced pituitary adenomas secrete prolactin and growth hormone Immunohistochemical studies using antisera immunoreactive to HMGA2 (Figure 3b) showed a strong nuclear staining, whereas no staining was observed without addition of the primary antibody (Figure 3a). Immunohistochemistry using antisera immunoreactive to murine pituitary hormones secreted from the anterior lobe was also carried out to de®ne the subtype of the pituitary adenomas. As shown in Figure 3, a strong cytoplasmic immunoreactivity for PRL (Figure 3c and e) and GH (Figure 3d and f) was observed, whereas only very rare cells show immunoreactivity for Luteinizing Hormone (LH), Thyroid-Stimulating Hormone (TSH), Follicle-Stimulating Hormone (FSH), Melanocyte-Stimulating Hormone (MSH) or Adrenocorticotropic Hormone (ACTH) (data not shown). These rare immunoreactive cells most likely represent residual entrapped cells of the normal adenohypophysis that has been massively expanded by tumour cells. To Oncogene

determine whether or not PRL immunoreactive cells were also producing GH, serial sections were stained with antisera raised against PRL and GH. As it appears by the comparison of the images, the tumour consists of at least two cell populations: those secreting prolactin (Figure 3c and e) and those secreting growth hormone (Figure 3d and f). These results correlate well with the ultrastructural ®ndings which indicate at least two populations of cells (Figure 2e): those with numerous dense core granules are fairly typical of growth hormone adenomas whereas cells with few dense core granules most likely represent prolactin producing cells. However, because we could not exclude the presence of a third population of mammosomatotroph cells secreting both hormones, cellular localization of GH and PRL was determined by in situ double immuno¯uorescent staining. As shown in Figure 4, the double red/green ¯uorescence of a pituitary adenoma from a HMGA2 mouse demonstrates the presence in the tumour of cells producing prolactin (green), growth hormone (red) and both hormones (yellow in the merging image). Thus, we conclude that the tumour consists of three dierent cell populations: one secreting GH, one secreting PRL and one secreting both hormones. The immunohistochemical results were con®rmed at the mRNA level by a semiquantitative RT ± PCR method. Figure 5a shows a drastic increase of GH


3193

Figure 2 (a) MRI analysis of a female transgenic mouse 11 months old (right) compared to a wild type control mouse (left). The arrow indicates a large tumour mass in the skull base. (b) Dorsal (left) and ventral (right) views of a typical transgenic brain of a 12 months old female. Attached to the brain, but easily detachable, is a large haemorrhagic mass spanning 2/3 of the extend of the brain. (c) Histological analysis, by hematoxylin and eosin (H and E) stain, of a HMGA2 pituitary adenoma (original magni®cation 1006). Asterisk marks the neurohypophysis in the center of the intermediate lobe of the pituitary. All around the cleft is the tumoral tissue that completely obliterated the anterior pituitary. (d) Primary culture of cells from a HMGA2 pituitary adenoma. (e) Ultrastructure of a HMGA2 pituitary adenoma by electron microscopy. Magni®cation of main image 52006. Inset in upper left corner shows structure of typical dense core granules

Table 1 Pathological ®ndings in HMGA2 transgenic mice Pathology Pituitary adenomas Large lactating secreting glands Micropolycystic kidney Large cell lymphoma Lung adenoma Pelvic lipomatosis Islet cell hyperplasia or adenoma Adrenal medullary hyperplasia Mucous metaplasia of the vagina Pheochromocytoma Mammary tumour Adrenal cortical hyperplasia or adenoma Ovary tumour Luteoma Mucous epithelial changes in cervix Thymic epithelial hyperplasia Hepatocellular carcinoma Hydronephrosis Chronic prostatitis Hypozoospermia

Females

Males

33/39 23/39 18/39 7/39 0/39 5/39 3/39 2/39 3/39 0/39 2/39 1/39 1/39 1/39 1/39 0/39 0/39 0/39 0/39 0/39

11/28 0/28 18/28 1/28 7/28 8/28 3/28 3/28 0/28 3/28 0/28 1/28 0/28 0/28 0/28 1/28 1/28 1/28 1/28 1/28

and PRL gene expression in a representative pituitary adenoma compared to pituitary glands from control mice. Densitometric analysis was carried out to quantify this increase and the results, relative to the mean+s.e. of three dierent adenoma samples, are reported in Figure 5b. Equally, pit-1, a gene encoding a transcriptional factor that has been shown to be critical for pituitary-speci®c activation of the GH and PRL genes, was expressed at high levels in pituitary adenomas, whereas its expression was not detectable at all in normal pituitary gland (Figure 5a, right panel). PRL and GH circulating levels in HMGA2 and control mice at dierent ages were analysed by a radioimmunological assay. As shown in Figure 5c, both PRL and GH serum levels start to increase signi®cantly, compared to control mice, at 6 months of age in transgenic females and at 18 months in transgenic males. Oncogene


3194

Figure 3 Immunohistochemical studies on HMGA2-induced pituitary adenomas using antisera immunoreactive to mouse pituitary hormones: (a) H and E staining. (b) Anti-HMGA2 antisera: strong, mainly nuclear staining was observed. (c) Anti-PRL antisera: strong cytoplasmic staining was observed in most of the cells. The inset shows the area reproduced in (e) at a higher magni®cation. (d) Anti-GH antisera: strong cytoplasmic staining was observed in many cells. The inset shows the area reproduced in (f) at a higher magni®cation; (c/e) and (d/f) are serial sections of the same adenoma area stained for PRL and GH, respectively. The cells producing GH and those producing prolactin are not the same

Other pathological findings in HMGA2 mice The postmortem examination of 39 female and 28 male HMGA2 transgenic mice, sacri®ced at 12 months of age, revealed pathological lesions other than the pituitary adenomas, with a generalized predisposition to tumour development. These results are summarized in Table 1. The majority of the HMGA2 mice showed large lactating mammary glands (Figure 6b) with the sporadic appearance of breast carcinomas (Figure 6d). The high secretion levels of PRL obviously account for this ®nding (Spady et al., 1999). In fact, it was not observed in transgenic mice with no pituitary adenomas. Another very frequent feature of these mice is the appearance of micropolycystic kidneys. As shown in Oncogene

Figure 6c, the kidney appears with multiple small cysts. This would suggest a certain role of the HMGA2 protein in kidney development. As described with the phenotype for mice carrying a truncated HMGA2 gene (Battista et al., 1999), HMGA2 mice also show abdominal/pelvic lipomatosis. However, this phenotype is less penetrant (20%) and the presence of fat tissue depots appears less abundant in these mice compared with the HMGA2/T mice (data not shown). Discussion To de®ne the role of HMGA2 overexpression in the process of tumorigenesis, we generated transgenic mice


Figure 4 In situ double immuno¯uorescence of HMGA2induced pituitary adenomas. Slices of pituitary adenomas from HMGA2 mice were processed for indirect immuno¯uorescence using Fluorescein (FITC: green stain), to reveal prolactin (Top Panel) and Texas red (TR: red stain), to reveal GH (Middle Panel). The bottom panel shows the merging image of the double red/green immuno¯uorescence labeling. Yellow spots are indicative of cells producing both PRL and GH hormones

carrying the wild type HMGA2 gene under the transcriptional control of a strong promoter, such as that of cytomegalovirus, able to drive a signi®cant and ubiquitous HMGA2 gene expression in adult tissues. Here we report the characterization of the most frequent pathological phenotype developed by these mice: a mixed growth hormone cell/prolactin cell pituitary adenoma. The pituitary adenomas show the presence of three cell types: one producing PRL

hormone, one producing GH hormone and one producing both the above hormones, suggesting a polyclonal origin of this neoplasia. However, we cannot exclude completely the possibility of a hyperplastic growth of cells able to dierentiate along these three histotypes. Interestingly, all the adenomas express high levels of Pit-1, which is a pituitary speci®c embryonic transcription factor constantly overexpressed in human pituitary adenomas secreting prolactin, growth hormone and/or TSH (PellegriniBouiller et al., 1997). It can be speculated that HMGA2 leads to hyperplasia of cells expressing Pit-1 or alternatively that the abnormal growth of the embryonic cells secreting GH and PRL may induce Pit-1 expression. The pituitary adenoma phenotype showed a high incidence in females, since it was present in 85% of the analysed mice. Conversely, only 40% of the males developed the same phenotype. The dierent hormonal background predisposing to this kind of tumour may account for these results (Spady et al., 1999). The high expression of PRL in females was responsible for mammary gland hyperplasia with lactating changes and the sporadic occurrence of breast adenocarcinomas. A high expression of PRL and GH was evidenced by the age of 6 months, although clinical symptoms appeared by the age of 12 months. These transgenic mice represent a valuable experimental model for PRL/ GH secreting pituitary adenomas. The high percentage of transgenic mice with pituitary adenomas, even though the transgene is expressed at high level in several mouse tissues other than pituitary gland, strongly indicates that the development of this neoplasia in mice overexpressing HMGA2 cannot be considered a non speci®c event. In fact, there is not a signi®cant appearance of other kind of tumours, apart from large cell lymphomas in females (18%) and lung adenomas in males (25%). In addition, the development of pituitary adenomas occurs also in transgenic animals expressing either a truncated HMGA2 or a full length HMGA1 transgene (M Fedele, unpublished data). These data, taken together suggest a critical role of the HMGA genes in the regulation of PRL and GH secreting pituitary cell growth. In a previous work from our laboratory, we have demonstrated that mice carrying a truncated HMGA2 gene, deprived of its carboxy-terminal tail (HMGA2/T mice), showed a drastic weight and size increase, with the presence of abdominal/pelvic lipomatosis (Battista et al., 1999). A similar phenotype was present also in the HMGA2 mice but with smaller fat pad depots and a relatively minor incidence (20%). Several hypotheses may be taken into consideration to explain this apparent discrepancy. First, the HMGA2/T mice have been generated following an ES mediated strategy that would allow a very high expression of the transgene, whereas the HMGA2 mice have been generated by the classical technique of microinjection of the transgene in fertilized eggs. Moreover, it is possible that the truncated HMGA2 form may show an increased

3195

Oncogene


3196

Figure 5 (a) RT ± PCR showing the expression of PRL, GH and Pit-1 in HMGA2-induced pituitary adenomas and in pituitary from control mice. The cDNAs were co-ampli®ed with b-actin as an internal control. (b) The dierences of PRL and GH mRNA levels in pituitary adenomas compared to pituitary from control mice were analysed by densitometric analyses and the results were plotted as an histogram. (c) GH and PRL serum levels at dierent ages. TG/F=transgenic females; WT/F=wild type females; TG/ M=transgenic males; WT/M=wild type males

activity in comparison with the wild type form. However, HMGA2 mice develop some pathology, such as micropolycystic kidney, not observed in HMGA2/T mice. These ®ndings would suggest a role of the HMGA2 gene in the development of other organs. Further studies are required to assess the role of the HMGA2 gene in these processes. Recent studies have shown that overexpression of the HMGA2 gene results in neoplastic transformation of rat ®broblast cells (Wood et al., 2000). However, the results presented here represent the ®rst evidence of an oncogenic role of HMGA2 overexpression in vivo. Interestingly, according to the ®nding of HMGA2 modi®cations in benign tumours, and with the low oncogenicity shown by a truncated HMGA2 construct (Fedele et al., 1998), HMGA2 overexpression is associated also in this case with benign tumours, such as the pituitary adenomas described here. A correlation between the phenotype induced by oncogenic activation in transgenic mice and the role of the same oncogenes in human pathology has been frequently demonstrated (Hogan, 1983). Therefore, we envisage a role of HMGA2 overexpression in human pituitary adenomas. Indeed, trisomy of chromosome 12, where the HMGA2 gene is located, represents the most frequent cytogenetic alteration in human PRLsecreting pituitary adenomas (Finelli et al., 2000). FISH analysis, using a HMGA2 PAC probe, shows ampli®cation of the HMGA2 locus associated with the Oncogene

induction of HMGA2 protein expression in human prolactinomas but not in other pituitary adenoma histotypes, strongly suggesting a critical role of HMGA2 overexpression in this kind of human neoplasias (Finelli et al., 2002).

Material and methods Generation of transgenic mice A fragment NruI ± PvuII (Figure 1a) containing the CMV promoter and the murine HMGA2 cDNA was microinjected into fertilized eggs of B6C3F2 mice that were then transferred to the oviducts of pseudopregnant females (Laboratory Animal Facility, Thomas Jeerson University, Philadelphia, PA, USA). Two transgenic founder mice were obtained and crossed to C57BL/6J wild type mice to establish transgenic lines. Germline transmission of the transgene was checked by Southern blot analysis of tail DNA from F1 ospring using a CMV fragment as probe. The expression of the HMGA2 transgene was evaluated in several tissues by a semiquantitative RT ± PCR-based assay, using a construct speci®c primer set, as already described (Battista et al., 1999). RNA extraction and RT ± PCR analyses Tissues from transgenic animals were rapidly dissected, frozen on dry ice and stored at 7808C. Total RNA was extracted using TRI-reagent solution (Molecular Research Center) according to the manufacturers protocol and treated


obtained with T1-weighting (TR/TE=400/11 ms). For light microscopy, tissues were ®xed by immersion in 10% formalin and embedded in paran by standard procedures. Five mm sections were stained with hematoxylin and eosin (H and E) or processed for the Immunohistochemistry. The immunoperoxidase staining was performed using the avidinbiotinperoxidase LSAB+kit (Dako) utilizing microwave antigen retrieval. The antisera used were directed to: HMGA2 (1 : 200); (Chiappetta et al., 1995), growth hormone (1 : 16 000) and prolactin (1 : 32 000). Growth hormone and prolactin antibodies were furnished by Dr AF Parlow, Scienti®c Director of the National Hormone and Pituitary Program. For Electron Microscopy, tissues were processed by standard procedures as previously described (Tsokos et al., 1987).

3197

In situ double immunofluorescence

Figure 6 Other pathological ®ndings in HMGA2 mice. (a) H and E staining of a mammary gland from a female control mouse: three normal alveolar ducts are shown among several adipocytic cells. (b) H and E staining of a mammary gland from a representative HMGA2 female mouse: an abnormally enlarged alveolar duct is shown with epithelial hyperproliferation and abundant lactating secretum in each cell. (c) H and E staining of kidney parenchyma from a representative HMGA2 mouse: multiple small cysts are shown. (d) MRI imagine of a HMGA2 female mouse: a mammary tumour (mt) is evident

with DNAse I (GenHunter Corporation). One mg of RNA was reverse transcribed according to manufacturers instructions (Perkin Elmer). The PCR ampli®cation was performed for 25 cycles (948C for 30 s, 558C for 30 s and 728C for 30 s). Primers designed to speci®cally amplify the transcripts of the transfected construct and the endogenous HMGA2 gene have been already described (Battista et al., 1999). The other primers used to speci®cally amplify mouse pituitary genes were: PRL (forward: 5' -CTCACTACATCCATACCCTG-3', reverse: 5'-TCCTTTGGCTTCAGGATAGG-3'); GH (forward: 5'-AGATCACTGCTTGGCAATGG-3', reverse: 5'GAAAACAGACTGGACAAGGG-3'); Pit-1 (forward: 5'CATTACTCTGTGCCTTCCTG-3', reverse: 5'-CTCAGTTCTCGGATTTCTG-3'). In addition, a set of primers speci®c for mouse b-actin (forward: 5'-GTCAGAAGGACTCCTATGTG-3', reverse: 5'-GCTCGTTGCCAATAGTGATG-3') was added to each reaction to serve as internal control for the amount of cDNA tested. Ampli®cation of RNA which was not reverse transcribed before PCR ampli®cation was performed as well (data not shown). The PCR products were separated on 2% agarose gels, blotted and hybridized with speci®c probes. MR imaging, histologic analysis, immunohistochemistry and electron microscopy Magnetic Resonance Imaging was performed on a 1.5-T magnet system (GE medical System) using local receiver coils and an 8-cm ®eld of view. Sagittal slices 3 mm thick were

Five mm thick sections were placed on ProbeOn slides (Fisher Biotech) and stained with anti-prolactin antisera (rabbit antimouse, 1 : 50) and anti-growth hormone antisera (guinea pig anti-mouse, 1 : 10) utilizing microwave antigen retrieval. Secondary antibodies included FITC conjugated anti-rabbit (1 : 100), and Texas Red conjugated anti-guinea pig (1 : 50) antisera. Serum hormone measurements Serum PRL and GH concentration was measured using mouse PRL and GH RIAs consisting of reagents provided by Dr AF Parlow. In terms of Mouse PRL AFP6476C: IOD Ag=Mouse PRL AFP10777D, antiserum=Anti-mPRL AFP131078 (Rabbit), ®nal dilution=1 : 500 000, BO/ T=36.0% and 37.1%. In terms of Mouse GH AFP10783B: IOD Ag=mGH AFP10783B, antiserum=NIDDK-Anti-Rat GH-RIA-5 (AFP), ®nal dilution=1 : 3 000 000, BO/ T=45.9%. All hormone measurements are expressed as mean+s.e.m. Primary cell cultures Pituitary cell primary cultures were carried out as previously described (Weil et al., 1998). Brie¯y, pure tumour was placed in cold saline and washed twice in PBS (pH 7.4), which contained penicillin-streptomycin (Sigma). Tumour was minced and incubated in sterile 0.1% Trypsin (Sigma) and 0.01% Dnase (Sigma) in HBSS (Life Technologies, Inc.) at 378C for 15 min. Cells were plated in poly-L-lysine (Sigma)coated 16-mm plates in DMEM/F-12 (Bio¯uids), with 10% FCS (Life Technologies, Inc.) and pen-strep, at 378C in 5% CO2.

Acknowledgments We thank Andrea Vecchione for useful discussions about the autoptic analysis of mice, Chris Munnery for the technical expertise in performing the in situ double immuno¯uorescence staining and the Associazione Partenopea per le Ricerche Oncologiche (APRO) for its support. This work was supported by grants P01CA76259 and P30CA56036 from the National Cancer Institute to CM Croce and by grants from AIRC and MURST, projects `Terapie antineoplastiche innovative' and `Piani di Potenziamento della Rete Scienti®ca e Tecnologica'. GM Pierantoni was supported by a fellowship from the FIRC. Oncogene


3198

References Abe N, Watanabe T, Sugiyama M, Uchimura H, Chiappetta G, Fusco A and Atomi Y. (1999). Cancer Res., 59, 1169 ± 1174. Abe N, Watanabe T, Masaki T, Mori T, Sugiyama M, Uchimura H, Fujioka Y, Chiappetta G, Fusco A and Atomi Y. (2000). Cancer Res., 60, 3117 ± 3122. Anand A and Chada K. (2000). Nat. Genet, 24, 377 ± 380. Arlotta P, Tai AK, Man®oletti G, Cliord C, Jay G and Ono SJ. (2000). J. Biol. Chem., 275, 14394 ± 14400. Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, Morton CC and Chada K. (1995). Cell, 82, 57 ± 65. Bandiera A, Bonifacio D, Man®oletti G, Mantovani F, Rustighi A, Zanconati F, Fusco A, Di Bonito L and Giancotti V. (1998). Cancer Res., 58, 426 ± 431. Battista S, Fidanza V, Fedele M, Klein-Szanto AJP, Outwater E, Brunner H, Santoro M, Croce CM and Fusco A. (1999). Cancer Res., 59, 4793 ± 4797. Bauer K, Carmeliet P, Schulz M, Baes M and Deuef C. (1990). Endocrinology, 127, 1224 ± 1233. Berlingieri MT, Man®oletti G, Santoro M, Bandiera A, Visconti R, Giancotti V and Fusco A. (1995). Mol. Cell. Biol., 15, 1545 ± 1553. Bol S, Wanschura S, Thode B, Deichert U, Van de Ven WJ, Bartnitzke S and Bullerdiek J. (1996). Cancer Genet. Cytogenet., 90, 88 ± 90. Chiappetta G, Bandiera A, Berlingieri MT, Visconti R, Man®oletti G, Battista S, Martinez-Tello FJ, Santoro M, Giancotti V and Fusco A. (1995). Oncogene, 10, 1307 ± 1314. Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti V, Santoro M, Simeone A and Fusco A. (1996). Oncogene, 13, 2439 ± 2446. Chiappetta G, Tallini G, De Biasio MC, Man®oletti G, Martinez-Tello FJ, Pentimalli F, de Nigris F, Mastro A, Botti G, Fedele M, Berger N, Santoro M, Giancotti V and Fusco A. (1998). Cancer Res., 58, 4193 ± 4198. Chiappetta G, Man®oletti G, Pentimalli F, Abe N, Di Bonito M, Vento MT, Giuliano A, Fedele M, Viglietto G, Santoro M, Watanabe T, Giancotti V and Fusco A. (2001). Int. J. Cancer, 91, 147 ± 151. Fedele M, Bandiera A, Chiappetta G, Battista S, Viglietto G, Man®oletti G, Casamassimi A, Santoro M, Giancotti V and Fusco A. (1996). Cancer Res., 56, 1896 ± 1901. Fedele M, Berlingieri MT, Scala S, Chiariotti L, Viglietto G, Rippel V, Bullerdiek J, Santoro M and Fusco A. (1998). Oncogene, 17, 413 ± 418. Fedele M, Battista S, Man®oletti G, Croce CM, Giancotti V and Fusco A. (2001). Carcinogenesis, 22, 1583 ± 1591.

Oncogene

Finelli P, Giardino D, Rizzi N, Buiatiotis S, Virduci T, Franzin A, Losa M and Larizza L. (2000). Int. J. Cancer, 86, 344 ± 350. Finelli P, Pierantoni GM, Giardino D, Losa M, Rodeschini O, Fedele M, Valtorta E, Mortini P, Croce CM, Larizza L and Fusco A. (2002). Cancer Res., in press. Giancotti V, Pani B, D'Andrea P, Berlingieri MT, Di Fiore PP, Fusco A, Vecchio G, Philp R, Crane-Robinson C, Nicolas RH, Wright CA and Goodwin GH. (1987). EMBO J., 6, 1981 ± 1987. Hogan B. (1983). Nature, 306, 313 ± 314. Johnson KR, Lehn DA and Reeves R. (1989). Mol. Cell. Biol., 9, 2114 ± 2123. Kazmierczak B, Wanschura S, Rosigkeit J, Mejer-Bolte K, Uschinsky K, Hanpt R, Schoenmakers EFPM, Barnitzke S, Van de Ven W and Bullerdiek J. (1995). Cancer Res., 55, 2497 ± 2499. Nagpal S, Ghosn C, DiSepio D, Molina Y, Sutter M, Klein ES and Chandraratna RAS. (1999). J. Biol. Chem., 274, 22563 ± 22568. Pellegrini-Bouiller I, Morange-Ramos I, Barlier A, Gunz G, Enjalbert A and Jaquet P. (1997). Horm. Res., 47, 251 ± 258. Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U and Bullerdiek J. (1996). Am. J. Pathol., 149, 775 ± 779. Rommel B, Rogalla P, Jox A, Kalle CV, Kazmierczak B, Wolf J and Bullerdiek J. (1997). 26, 603 ± 607. Schoenberg Fejzo M, Ashar HR, Krauter KS, Powell WL, Rein MS, Weremowicz S, Yoon SJ, Kucherlapati RS, Chada K and Morton CC. (1996). Genes Chrom. Cancer, 17, 1 ± 6. Schoenmakers EFPM, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H and Van de Ven WJ. (1995). Nat. Genet., 10, 436 ± 444. Spady TJ, McComb RD and Shull JD. (1999). Endocrine, 11, 217 ± 233. Staats B, Wanschura S, Hanisch P, Schoenmakers EF, Van de Ven WJ, Bartnitzke S and Bullerdiek J. (1996). Breast Cancer Res. Treat., 38, 299 ± 303. Thanos D and Maniatis T. (1995). Cell, 83, 1091 ± 1100. Tsokos M, Scarpa S, Ross RA and Triche TJ. (1987). Am. J. Pathol., 128, 484 ± 496. Weil RJ, Huang S, Pack S, Vortmeyer AO, Tsokos M, Lubensky IA, Old®eld EH and Zhuang Z. (1998). Cancer Res., 58, 4715 ± 4720. Wood LJ, Maher JF, Bunton TE and Resar LM. (2000). Cancer Res., 60, 4256 ± 4261. Zhou X, Benson KF, Ashar HR and Chada K. (1995). Nature, 376, 771 ± 774.